4/18
09:17 am
onct
Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer [Yahoo! Finance]
Medium
Report
Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer [Yahoo! Finance]
4/18
09:00 am
onct
Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
Medium
Report
Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
4/17
02:07 am
onct
Oncternal Therapeutics, Inc. (NASDAQ: ONCT) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Low
Report
Oncternal Therapeutics, Inc. (NASDAQ: ONCT) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
4/15
08:11 am
onct
Oncternal Therapeutics, Inc. (NASDAQ: ONCT) had its price target lowered by analysts at HC Wainwright from $30.00 to $28.00. They now have a "buy" rating on the stock.
Medium
Report
Oncternal Therapeutics, Inc. (NASDAQ: ONCT) had its price target lowered by analysts at HC Wainwright from $30.00 to $28.00. They now have a "buy" rating on the stock.
4/11
01:14 pm
onct
AIVITA Biomedical CEO Dr. Hans Keirstead and CMO Dr. Robert Dillman to Speak and Participate in Keynote Panel at Festival of Biologics USA [Yahoo! Finance]
Low
Report
AIVITA Biomedical CEO Dr. Hans Keirstead and CMO Dr. Robert Dillman to Speak and Participate in Keynote Panel at Festival of Biologics USA [Yahoo! Finance]
3/15
09:00 am
onct
Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer
Low
Report
Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer
3/8
11:04 pm
onct
Oncternal Therapeutics, Inc. (NASDAQ: ONCT) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Low
Report
Oncternal Therapeutics, Inc. (NASDAQ: ONCT) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
3/8
10:41 am
onct
Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
3/7
04:09 pm
onct
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]
Medium
Report
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]
3/7
04:01 pm
onct
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
Medium
Report
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
2/29
04:05 pm
onct
Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results
Medium
Report
Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results
2/25
09:23 am
onct
Oncternal Therapeutics (NASDAQ:ONCT) Will Have To Spend Its Cash Wisely [Yahoo! Finance]
Low
Report
Oncternal Therapeutics (NASDAQ:ONCT) Will Have To Spend Its Cash Wisely [Yahoo! Finance]
2/6
04:48 pm
onct
Oncternal Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
Low
Report
Oncternal Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
2/6
04:30 pm
onct
Oncternal Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference
Low
Report
Oncternal Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference
2/1
09:00 am
onct
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Neutral
Report
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
1/29
08:12 am
onct
Oncternal Therapeutics, Inc. (NASDAQ: ONCT) had its price target raised by analysts at HC Wainwright from $2.00 to $30.00. They now have a "buy" rating on the stock.
Medium
Report
Oncternal Therapeutics, Inc. (NASDAQ: ONCT) had its price target raised by analysts at HC Wainwright from $2.00 to $30.00. They now have a "buy" rating on the stock.
1/26
01:47 am
onct
Oncternal Therapeutics, Inc. (NASDAQ: ONCT) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
Oncternal Therapeutics, Inc. (NASDAQ: ONCT) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.